Cardiovascular Oncology: Consensus Statements Are Still Lacking to Improve the Management of Side-Effects of Old and New Chemotherapeutic Agents.

IF 2.2 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Angiology Pub Date : 2025-07-29 DOI:10.1177/00033197251356583

Antonio V Sterpetti, Francesca Miceli, Alessia Di Girolamo, Immacolata Iannone, Paolo Sapienza, Luca Di Marzo

{"title":"Cardiovascular Oncology: Consensus Statements Are Still Lacking to Improve the Management of Side-Effects of Old and New Chemotherapeutic Agents.","authors":"Antonio V Sterpetti, Francesca Miceli, Alessia Di Girolamo, Immacolata Iannone, Paolo Sapienza, Luca Di Marzo","doi":"10.1177/00033197251356583","DOIUrl":null,"url":null,"abstract":"<p><p>Significant advances in diagnostic methods and better life-expectancy have resulted in increased number of patients with cardiovascular diseases and cancer. Elderly patients are at risk for both diseases, and the treatment of patients with cardiovascular and oncologic problems represents a daily clinical challenge, considering the heterogeneity of clinical situations. The present review underlines the complexity of cardiovascular oncology. In the last 5 years >18 new drugs against cancer, with possible cardiovascular side-effects, were approved by the Food and Drug Administration. Several new drugs are under evaluation in multicenter prospective studies, and some of these agents have potential cardiovascular side-effects. This review analyzes the difficulties for cardiovascular specialists to keep updated regarding the possible side-effects of new chemotherapeutic agents. The analysis of the mechanisms involved in cancer occurrence and progression are a field of research in continuous development with new discoveries, and technologies applied at developing effective chemotherapeutic drugs. Several recommendations have been proposed by the American Heart Association and European Society of Cardiology, promoting the need for close collaboration between cardiologists, surgeons, and oncologists. It is important to develop strategies to support training in cardiovascular oncology.</p>","PeriodicalId":8264,"journal":{"name":"Angiology","volume":" ","pages":"33197251356583"},"PeriodicalIF":2.2000,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Angiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00033197251356583","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Significant advances in diagnostic methods and better life-expectancy have resulted in increased number of patients with cardiovascular diseases and cancer. Elderly patients are at risk for both diseases, and the treatment of patients with cardiovascular and oncologic problems represents a daily clinical challenge, considering the heterogeneity of clinical situations. The present review underlines the complexity of cardiovascular oncology. In the last 5 years >18 new drugs against cancer, with possible cardiovascular side-effects, were approved by the Food and Drug Administration. Several new drugs are under evaluation in multicenter prospective studies, and some of these agents have potential cardiovascular side-effects. This review analyzes the difficulties for cardiovascular specialists to keep updated regarding the possible side-effects of new chemotherapeutic agents. The analysis of the mechanisms involved in cancer occurrence and progression are a field of research in continuous development with new discoveries, and technologies applied at developing effective chemotherapeutic drugs. Several recommendations have been proposed by the American Heart Association and European Society of Cardiology, promoting the need for close collaboration between cardiologists, surgeons, and oncologists. It is important to develop strategies to support training in cardiovascular oncology.

查看原文本刊更多论文

心血管肿瘤学：在改进新旧化疗药物副作用管理方面仍缺乏共识声明。

诊断方法的重大进步和预期寿命的延长导致心血管疾病和癌症患者人数增加。老年患者有患这两种疾病的风险，考虑到临床情况的异质性，心血管和肿瘤问题患者的治疗是日常临床挑战。本综述强调了心血管肿瘤学的复杂性。在过去的5年里，美国食品和药物管理局批准了18种可能对心血管产生副作用的抗癌新药。一些新药正在多中心前瞻性研究中进行评估，其中一些药物具有潜在的心血管副作用。这篇综述分析了心血管专科医生在了解新化疗药物可能产生的副作用方面所面临的困难。癌症发生和发展的机制分析是一个不断发展的研究领域，新的发现和技术应用于开发有效的化疗药物。美国心脏协会和欧洲心脏病学会提出了几项建议，促进了心脏病专家、外科医生和肿瘤学家之间密切合作的必要性。制定支持心血管肿瘤学培训的策略是很重要的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Angiology 医学-外周血管病

CiteScore

5.50

自引率

14.30%

发文量

180

审稿时长

6-12 weeks

期刊介绍： A presentation of original, peer-reviewed original articles, review and case reports relative to all phases of all vascular diseases, Angiology (ANG) offers more than a typical cardiology journal. With approximately 1000 pages per year covering diagnostic methods, therapeutic approaches, and clinical and laboratory research, ANG is among the most informative publications in the field of peripheral vascular and cardiovascular diseases. This journal is a member of the Committee on Publication Ethics (COPE). Average time from submission to first decision: 13 days